Aim: Efficacy of Methylprednisolone with Dexamethasone in patients with severe COVID pneumonia in term of clinical and biochemical improvement.

Methodology: Cross Sectional analytical study conducted among COVID-19 patients admitted in HDU of Sir Sadiq Hospital, Bahawalpur from May, 2021 to June 2021 after taking approval from institutional ethical committee. 82 patients were included in this study after taking informed consent. Patients were divided into two groups A and B i.e.  I/V methyl prednisolone and I/V dexamethasone respectively. Each group was containing 41 patients. Primary outcome was measured in terms of decrease or increase in oxygen demand leading to discharge or shifting to Intensive Care Unit. CRP levels were also measured to assess biochemical improvement.

Results: 31 (75.6%) patients from group A and 22(53.7%) from group B were improved and discharged and difference was statistically significant (p<0.05). Number of patients shifted to ICU were 10(24.4%) and 19(46.3%) from A and B groups respectively.

Conclusion: In terms of clinical and biochemical response methylprednisolone outperforms dexamethasone.

Keywords: Methylprednisolone, Dexamethasone, COVID pneumonia,